These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2775763)

  • 1. Topo-dynamic characteristics of human plasma VLDL apolipoproteins and efficiency of triacylglycerol hydrolysis by lipoprotein lipase.
    Dergunov AD; Shuvaev VV; Perova NV
    Biochim Biophys Acta; 1989 Sep; 1005(1):79-86. PubMed ID: 2775763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dynamic behavior of apoproteins of human plasma very low density lipoproteins and lipolysis regulation].
    Dergunov AD; Shuvaev VV; Perova NV
    Biokhimiia; 1990 Jan; 55(1):134-46. PubMed ID: 2160840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLDL substrate properties and efficiency of their metabolic transformation by LPL.
    Dergunov AD; Shuvaev VV; Perova NV
    Experientia; 1989 May; 45(5):461-3. PubMed ID: 2721636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein lipase-catalyzed hydrolysis of phosphatidylcholine of guinea pig very low density lipoproteins and discoidal complexes of phospholipid and apolipoprotein: effect of apolipoprotein C-II on the catalytic mechanism.
    Shirai K; Fitzharris TJ; Shinomiya M; Muntz HG; Harmony JA; Jackson RL; Quinn DM
    J Lipid Res; 1983 Jun; 24(6):721-30. PubMed ID: 6688442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
    Campos H; Perlov D; Khoo C; Sacks FM
    J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.
    Westerterp M; de Haan W; Berbée JF; Havekes LM; Rensen PC
    J Lipid Res; 2006 Jun; 47(6):1203-11. PubMed ID: 16537968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content.
    Khoo C; Campos H; Judge H; Sacks FM
    J Lipid Res; 1999 Feb; 40(2):202-12. PubMed ID: 9925648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
    Dinkel RE; Barrett PH; Demant T; Parhofer KG
    Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.
    Jong MC; Rensen PC; Dahlmans VE; van der Boom H; van Berkel TJ; Havekes LM
    J Lipid Res; 2001 Oct; 42(10):1578-85. PubMed ID: 11590213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of lipids, lipoproteins, and apolipoproteins in Menkes' disease.
    Blackett PR; Lee DM; Donaldson DL; Fesmire JD; Chan WY; Holcombe JH; Rennert OM
    Pediatr Res; 1984 Sep; 18(9):864-70. PubMed ID: 6483510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject.
    Huff MW; Evans AJ; Wolfe BM; Connelly PW; Maguire GF; Strong WL
    J Lipid Res; 1990 Mar; 31(3):385-96. PubMed ID: 2341805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
    Wang CS; Alaupovic P; Gregg RE; Brewer HB
    Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of phosphatidylcholine liposomes on the compositional changes of VLDL during lipoprotein lipase (LPL)-mediated lipolysis.
    Ćwiklińska A; Gliwińska A; Senderowska Z; Kortas-Stempak B; Kuchta A; Dąbkowski K; Jankowski M
    Chem Phys Lipids; 2016 Feb; 195():63-70. PubMed ID: 26756862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high carbohydrate-fat free diet alters the proportion of heparin-bound VLDL in plasma and the expression of VLDL-apoB-100 epitopes.
    Keidar S; Goldberg AC; Cook K; Bateman J; Schonfeld G
    Metabolism; 1990 Mar; 39(3):281-8. PubMed ID: 2308518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing structure and function of VLDL by synthetic amphipathic helical peptides.
    Chung BH; Palgunachari MN; Mishra VK; Chang CH; Segrest JP; Anantharamaiah GM
    J Lipid Res; 1996 May; 37(5):1099-112. PubMed ID: 8725161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of C-apolipoproteins in the enzymatic interconversions of plasma lipoproteins.
    Kinnunen PK; Vainio P; Virtanen JA
    Ric Clin Lab; 1982; 12(1):41-9. PubMed ID: 7046022
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.